Farrar GJ - Search Results

1

Emerging therapeutic approaches for osteogenesis imperfecta.

Millington-Ward S, McMahon HP, Farrar GJ. Millington-Ward S, et al. Among authors: farrar gj. Trends Mol Med. 2005 Jun;11(6):299-305. doi: 10.1016/j.molmed.2005.04.006. Trends Mol Med. 2005. PMID: 15949772 Review.

2

Clinical and molecular genetic characterisation of a family segregating autosomal dominant retinitis pigmentosa and sensorineural deafness.

Kenna P, Mansergh F, Millington-Ward S, Erven A, Kumar-Singh R, Brennan R, Farrar GJ, Humphries P. Kenna P, et al. Among authors: farrar gj. Br J Ophthalmol. 1997 Mar;81(3):207-13. doi: 10.1136/bjo.81.3.207. Br J Ophthalmol. 1997. PMID: 9135384 Free PMC article.

3

Strategems in vitro for gene therapies directed to dominant mutations.

Millington-Ward S, O'Neill B, Tuohy G, Al-Jandal N, Kiang AS, Kenna PF, Palfi A, Hayden P, Mansergh F, Kennan A, Humphries P, Farrar GJ. Millington-Ward S, et al. Among authors: farrar gj. Hum Mol Genet. 1997 Sep;6(9):1415-26. doi: 10.1093/hmg/6.9.1415. Hum Mol Genet. 1997. PMID: 9285777

4

Retinitis pigmentosa and progressive sensorineural hearing loss caused by a C12258A mutation in the mitochondrial MTTS2 gene.

Mansergh FC, Millington-Ward S, Kennan A, Kiang AS, Humphries M, Farrar GJ, Humphries P, Kenna PF. Mansergh FC, et al. Among authors: farrar gj. Am J Hum Genet. 1999 Apr;64(4):971-85. doi: 10.1086/302344. Am J Hum Genet. 1999. PMID: 10090882 Free PMC article.

5

A mutation-independent therapeutic strategem for osteogenesis imperfecta.

Millington-Ward S, O'Neill B, Kiang AS, Humphries P, Kenna PF, Farrar GJ. Millington-Ward S, et al. Among authors: farrar gj. Antisense Nucleic Acid Drug Dev. 1999 Dec;9(6):537-42. doi: 10.1089/oli.1.1999.9.537. Antisense Nucleic Acid Drug Dev. 1999. PMID: 10645780

6

Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.

O'Neill B, Millington-Ward S, O'Reilly M, Tuohy G, Kiang AS, Kenna PF, Humphries P, Farrar GJ. O'Neill B, et al. Among authors: farrar gj. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2863-9. Invest Ophthalmol Vis Sci. 2000. PMID: 10967039

7

Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta.

Millington-Ward S, Allers C, Tuohy G, Conget P, Allen D, McMahon HP, Kenna PF, Humphries P, Farrar GJ. Millington-Ward S, et al. Among authors: farrar gj. Hum Mol Genet. 2002 Sep 15;11(19):2201-6. doi: 10.1093/hmg/11.19.2201. Hum Mol Genet. 2002. PMID: 12217948

8

Sensitivity of photoreceptor-derived cell line (661W) to baculoviral p35, Z-VAD.FMK, and Fas-associated death domain.

Tuohy G, Millington-Ward S, Kenna PF, Humphries P, Farrar GJ. Tuohy G, et al. Among authors: farrar gj. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3583-9. Invest Ophthalmol Vis Sci. 2002. PMID: 12407171

9

RNAi of COL1A1 in mesenchymal progenitor cells.

Millington-Ward S, McMahon HP, Allen D, Tuohy G, Kiang AS, Palfi A, Kenna PF, Humphries P, Farrar GJ. Millington-Ward S, et al. Among authors: farrar gj. Eur J Hum Genet. 2004 Oct;12(10):864-6. doi: 10.1038/sj.ejhg.5201230. Eur J Hum Genet. 2004. PMID: 15241481

10

Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach.

Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, Kennan A, O'reilly M, Tam LC, Aherne A, McNally N, Humphries P, Farrar GJ. Kiang AS, et al. Among authors: farrar gj. Mol Ther. 2005 Sep;12(3):555-61. doi: 10.1016/j.ymthe.2005.03.028. Mol Ther. 2005. PMID: 15967729 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page